| Customization: | Available |
|---|---|
| CAS No.: | 877399-52-5 |
| Molecular Formula: | C21h22cl2fn5o |
|
Still deciding? Get samples of US$ 350/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Crizotinib |
| CAS: | 877399-52-5 |
| Molecular Formula: | C21H22Cl2FN5O |
| Molecular Weight: | 450.34 |
| Purity | 99% |
Crizotinib is a type of cancer drug called a kinase inhibitor that is used to treat two rare forms of cancer.
Crizotinib is used to treat a type of non-small cell lung cancer (NSCLC) in people with an error in genes called ROS1 or ALK (anaplastic lymphoma kinase). An ROS1 error occurs in about 1 percent of people with NSCLC, while and ALK error occurs in about 5 percent of cases.
Defects in ROS1 and ALK cause cells to grow out of control causing cancer. Crizotinib works to help stop or slow the growth of cancer. It does this by blocking the action of ROS1 and ALK. It is known as a ROS1 tyrosine kinase inhibitor and an ALK tyrosine kinase inhibitor.
When Crizotinib was approved by the US Food and Drug Administration (FDA) in 2011, it was the first therapy to be approved for patients with ROS1-positive NSCLC.
Crizotinib is also used to treat a rare form of non-Hodgkin lymphoma (NHL) in children and young adults called anaplastic large cell lymphoma (ALCL) that has a defect in the ALK gene. About 90 percent of cases of ALCL in young people are ALK-positive.
){kind=link}